1. Home
  2. ARCT vs GANX Comparison

ARCT vs GANX Comparison

Compare ARCT & GANX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Arcturus Therapeutics Holdings Inc.

ARCT

Arcturus Therapeutics Holdings Inc.

HOLD

Current Price

$7.55

Market Cap

192.6M

Sector

Health Care

ML Signal

HOLD

Logo Gain Therapeutics Inc.

GANX

Gain Therapeutics Inc.

HOLD

Current Price

$1.80

Market Cap

159.2M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
ARCT
GANX
Founded
2013
2017
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
192.6M
159.2M
IPO Year
N/A
2021

Fundamental Metrics

Financial Performance
Metric
ARCT
GANX
Price
$7.55
$1.80
Analyst Decision
Buy
Strong Buy
Analyst Count
11
6
Target Price
$38.44
$8.00
AVG Volume (30 Days)
510.7K
865.6K
Earning Date
03-05-2026
03-26-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$97,601,000.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$5.85
$1.41
52 Week High
$24.17
$4.34

Technical Indicators

Market Signals
Indicator
ARCT
GANX
Relative Strength Index (RSI) 49.62 32.04
Support Level $7.00 $1.61
Resistance Level $7.95 $2.07
Average True Range (ATR) 0.37 0.15
MACD -0.02 0.00
Stochastic Oscillator 30.00 5.66

Price Performance

Historical Comparison
ARCT
GANX

About ARCT Arcturus Therapeutics Holdings Inc.

Arcturus Therapeutics Holdings Inc is an RNA medicines company focused on the development of infectious disease vaccines and opportunities within liver and respiratory rare diseases. It operates in one business segment, which includes all activities related to the discovery, development, and commercialization of messenger RNA medicines. The company's pipeline includes LUNAR-OTC and LUNAR-CF. Its Vaccine candidates include LUNAR-FLU, KOSTAIVE XBB.1.5, KOSTAIVE, and Others.

About GANX Gain Therapeutics Inc.

Gain Therapeutics Inc is a biotechnology company developing novel small molecule therapeutics to treat diseases across several therapeutic areas, including, lysosomal storage disorders, central nervous system disorders, metabolic disorders, and oncology. The company's clinical-stage product candidate, GT-02287, is being developed for the treatment of GBA1 Parkinson's disease. The company uses its computational target and drug discovery platform, Magellan, to discover novel allosteric binding sites on proteins implicated in disease and to identify proprietary small molecules that bind these sites to modulate protein function and treat the underlying cause of the disease. Geographically, the company operates in Switzerland, Spain, the United States, and Australia.

Share on Social Networks: